Treated group: Myo-Ins 1.1 g + D-chiro-Ins 27.6 mg + FA 400 μg/d Control group: FA 400 μg/d
Number = 46 Treated: 21 Control: 25
Age: <35 years, BMI >30 kg/m2, and PCOS according to Rotterdam criteria
Diabetic subjects, smokers, and alcohol users
FSH, LH, E2, SHBG, A, free T, DHEA-S, HOMA index, and fasting glucose and insulin
Myo-Ins, myo-inositol; D-chiro-Ins, D-chiro-inositol; FA, folic acid; PCOS, polycystic ovary syndrome; PRL, prolactin; E2, oestradiol; A, androstenedione; 17OHP, 17-hydroxyprogesterone; T, testosterone; P, progesterone; OGTT, oral glucose tolerance; BMI, body mass index; LH, luteinizing hormone; FSH, follicle stimulating hormone; DHEAS, dehydroepiandrosterone; SHBG, sex hormone binding globulin; AUC, area under the curve of OGTT; VLDL, very-low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; WHR, waist-to-hip ratio. OGTT performed sampling 15 minutes before and 30, 60, 90, 120, and 240 minutes after the oral assumption of 75 g of glucose. Adams et al. .
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.